MetaCap

BioAge Labs (BIOA) vs Cartesian Therapeutics (RNAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cartesian Therapeutics (RNAC) has outperformed BioAge Labs (BIOA) over the past year, losing 15.2% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $187.3 million), about 1.1 times the size. BioAge Labs converts more of its revenue into profit, with a net margin of -896.1% versus -4658.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIOA-50.52%RNAC-15.19%
+202%+70%-63%
Nov 21, 20251 yearNov 20, 2026
BIOA-79.62%RNAC-63.88%
+54%-18%-91%
Sep 23, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIOA versus RNAC key metrics
MetricBIOARNAC
Share price$4.28$6.14
Market cap$196.67M$187.29M
1-day change-9.13%+4.24%
YTD return-67.65%-14.84%
1-year return-50.52%-15.19%
5-year return—-92.94%
EPS (TTM)$-2.56$-4.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.99M$2.80M
Revenue growth (YoY)—-92.81%
Net income (latest FY)$-80.61M$-130.30M
Operating margin-1031.46%-5127.10%
Net margin-896.11%-4658.63%
52-week high$25.96$11.00
52-week low$4.24$5.60
Distance from 52-week high-83.51%-44.18%
Analyst consensusbuystrong_buy
Avg. price target upside+572.43%+448.37%
Average volume740.06K139.65K
Shares outstanding45.95M30.50M
Employees6075
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNAC has outperformed BIOA by 35.3 percentage points over the past year.
  • BioAge Labs is more profitable, keeping -896.1 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.

About BioAge Labs

BIOA stock →

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Cartesian Therapeutics

RNAC stock →

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

BIOA vs RNAC FAQ

Which is bigger, BioAge Labs or Cartesian Therapeutics?

BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $187.29M for Cartesian Therapeutics (RNAC).

Which stock has performed better over the past year, BIOA or RNAC?

RNAC returned -15.19% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.

Are BioAge Labs and Cartesian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons